Yingying Wang1,2†Baiyan Wang1†Yangfan Xiao2Qingchun Cai3Junyue Xing2
Hao Tang2*Ruiqin Li4*Hongtao Zhang5,6,7,8*- 1Medical College, Henan University of Chinese Medicine, Zhengzhou, Henan, China
- 2National Health Commission Key Laboratory of Cardiovascular Regenerative Medicine, Heart Center of Henan Provincial People’s Hospital, Fuwai Central China Cardiovascular Hospital and Central China Branch of National Center for Cardiovascular Diseases, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, Henan, China
- 3Department of Clinical Lab, The Third Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China
- 4Academy of Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou, Henan, China
- 5Blood Purification Center, The People’s Hospital of Zhengzhou University, Zhengzhou, China
- 6Blood Purification Center, Henan Provincial People’s Hospital, Zhengzhou, China
- 7Institute of Nephrology, Mathura, Henan, China
- 8Department of Nephrology Henan Provincial People’s Hospital, Zhengzhou, China
A Correction on
Baicalin-modified polyethylenimine for miR-34a efficient and safe delivery
by Wang Y, Wang B, Xiao Y, Cai Q, Xing J, Tang H, Li R and Zhang H (2023). Front. Bioeng. Biotechnol. 11:1290413. doi: 10.3389/fbioe.2023.1290413
In the published article, there was an error in Western blot of Figure 4C as published. An extra GAPDH band image was included in the original Figure 4C. The corrected Western blot of Figure 4C and its caption FIGURE 4 BA-PEI/miR-34a induced apoptosis of tumor cell A549. (C) Western blots used to analyze the apoptotic protein (pro-caspase-3, -8, and -9 and PTEN), based on the control, miR-34a, PEI, BA-PEI, PEI/miR-34a, and BA-PEI/miR-34a. appear below.
Figure 4. BA-PEI/miR-34a induced apoptosis of tumor cell A549. (A) Cell apoptosis analysis using flow cytometry, based on the control, miR-34a, PEI, BAPEI, PEI/miR-34a, and BA-PEI/miR-34a. (B) Quantitative analysis of (A). (C) Western blots used to analyze the apoptotic protein (pro-caspase-3, -8, and -9 and PTEN), based on the control, miR-34a, PEI, BA-PEI, PEI/miR-34a, and BA-PEI/miR-34a. (D) Quantitative analysis of (C). *p <0.05; **p <0.01; ns, not significant.
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: baicalin, lung cancer, gene therapy, miR-34a, hydrophobic modification
Citation: Wang Y, Wang B, Xiao Y, Cai Q, Xing J, Tang H, Li R and Zhang H (2025) Correction: Baicalin-modifed polyethylenimine for miR-34a efficient and safe delivery. Front. Bioeng. Biotechnol. 13:1631667. doi: 10.3389/fbioe.2025.1631667
Received: 20 May 2025; Accepted: 30 June 2025;
Published: 15 July 2025.
Edited and reviewed by:
Gianni Ciofani, Italian Institute of Technology (IIT), ItalyCopyright © 2025 Wang, Wang, Xiao, Cai, Xing, Tang, Li and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hao Tang, dGFuZ3BrdV96enVoYW9Aenp1LmVkdS5jbg==; Ruiqin Li, bGlycWluQHllYWgubmV0; Hongtao Zhang, emh0enp1QHp6dS5lZHUuY24=
†These authors have contributed equally to this work